145020 J.P. Morgan HealthCare…

Page 1

J.P. Morgan Healthcare Conference Speaker: Eva Huang January, 2025

Page 2

This document is for the presentation of Hugel, Inc.(“Company”) and provided for the convenience of investors only. This presentation may contain "forward-looking statements" - that is, statements related to future, not past, events. In this context, "forward- looking statements" often address our expected future business and financial performance, and often contain words such as "expects”, "anticipates”, "intends”, "plans”, "believes”, "seeks” or "will ". “Forward-looking statements" by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause our actual results to be materially different from those expressed in this document. The Company may make changes to or update this presentation or the contents at any time without notice. No user of this document may republish, copy, reproduce, modify, post, transmit or distribute in any way any portion of this presentation without the prior written consent of the Company. By attending the presentation, you agree that all matters relating to violation of the above restriction shall be governed by the Capital Market laws of Korea. January, 2025 2 Disclaimer

Page 3

3 1 2 3 4 Table of Contents

Page 4

Market Leadership & Global Expansion No.1 24 Years Top 5 Korean Market Leadership of Toxin & HA Filler Safety and quality track record Global Toxin Player in 67 countries Significant Potential Upside Total Aesthetic Toxin and Filler Market Size (2024~2030E) Global Penetration Rate (2023) 5.6% Solid Financials KRW451bn Cash Balance and No Debt as of 3Q 2024 31.1% EBITDA Growth % (2023-3Q LTM 2024) 47.4% EBITDA Margin% (3Q LTM 2024) 4 One and only Asian company to obtain toxin approvals in Top 3 Markets, US, China and Europe 77.2% Cash Conversion Rate 3Q LTM 2024 Global Toxin Expansion by 2028 67  80 Countries 2024 2030 US$10.8bn  22.4bn Hugel Snapshot

Page 5

Hugel’s Medical Aesthetics Product Portfolio Botulinum Toxin (55% revenue contribution in 3Q LTM 2024) Filler & Skin Booster (34% revenue contribution in 3Q LTM 2024) Absorbable Thread (2% revenue contribution in 3Q LTM 2024) Cosmeceutical (9% revenue contribution in 3Q LTM 2024) Botulax, Letybo  Offered in 50U/100U/150U/200U/300U to cater to different volume needs by application area Forehead Glabella Lines PDO Thread Masseter Muscle Whole Face Crow’s Feet Glabella Eye Nose Cheek Lip Chin Blue Rose Forte, Blue Rose Clair  Medical absorbable thread used for lifting and tightening facial skin The Chaeum, Dermalax, Persnica, BYRYZN  Comprehensive line-ups covering various consumer needs from volumizing to skin boosting  Wellage, BYRYZN BR  Highly functional cosmetics using pure and concentrated ingredients with key focus on hydrating, firming, and whitening lines 5

Page 6

Net Sales Trend '10 '11 '12 '13 '14 '15 '16 '17 '18 '19 '20 '21* '22 '23 3Q LTM 2024 Toxin Filler Others 21.0 29.0 40.3 65.1 124.2 182.1 182.4 204.6 211.0 231.9 8.0 16.0 (54%) (38%) (8%) [Unit: KRWbn] 281.7 (57%) (33%) (10%) 319.7 (10%) (37%) (53%) 363.8 (55%) (35%) Solid leadership position in the Korean toxin/filler market Evolution into the global bio aesthetic industry leader Product development and Foundation of domestic market Harvesting: Period of visible, exponential growth and profitability Hugel’s Growth History with Product and Global Expansion • International expansion with additional sales volume and higher ASP • Continuous margin improvement • Further M&A and global platform building (10%) 6

Page 7

Key Development Pillars 2028F Outlook Mission Global Leading Medical Aesthetic Company Dedicated to Improving the Quality and Happiness of Mankind Toxin Countries 80+ Filler Countries 70+ Cosmeceutical Countries 10+ Focused Portfolio with Synergic Diversity 55% Toxin 34% Filler 9% 2% Toxin Filler Cosmeceutical Absorbable Thread Balanced Global Presence with Strong Growth Engines Continuous Upsides from Further Operation Optimization  Expansion to higher ASP markets  Conversion from distribution model to direct for select prioritized markets  Manufacturing and operation efficiency Toxin and filler account for ~90% of total revenue  Continued to be anchor products in the portfolio Korea U.S. ChinaEU MENA Others Korea U.S. China Europe MENA Others Hugel Vision 7

Page 8

Key Updates2024 Key Financial Performance* ITC concluded “There is NO violation of Section 337” in final determination 2 U.S. FDA approval of botulinum toxin, Letybo 50/100 units received3 Toxin Approvals in Malaysia; Strengthened strategic partnership to enter MENA 4 On Track to Deliver 30%+ YoY EBITDA Growth for 20245 Hugel’s new high end cosmetics brand, ‘BYRYZN BR’ launched6 Strengthened Management Capabilities1 *based on 3Q LTM 2024 2023~2024: Key Updates 8

Page 9

 In April 2023, Suk Cha joined Hugel as Executive Chairman. Mr. Cha brings over 35 years of expertise in the consumer and healthcare industries  Under Chairman Cha’s leadership, Hugel achieved various milestones such as a Clean win of ITC litigation for Hugel, US FDA approval, revision of key market strategies, consistent financial growth, strong margin improvement etc. Suk Cha Executive Chairman Chairman of the Board  Over 35 years of expertise in the consumer and healthcare industries  Extensive experience leading business transformation and integration across multiple industries  Successfully directed multiple M&A transactions including LG Household & Health Care’s acquisitions of CNP Cosmetics, Physiogel and The Coca-Cola Beverage Company  Mr. Cha received his MBA degree from Cornell University's SC Johnson College of Business About Suk Cha  Mr. Cha served as the Chairman & CEO of LG Household & Health Care for 18 years and also assumed the role of Chairman of LG Group Companies. He is publicly recognized as the key figure in achieving a record delivery of 17 consecutive years of growth at LG H&H and leading its global market expansion into China, North America, and Japan  Prior to that, Mr. Cha served as the President & CEO of Haitai Confectionary & Foods  From 1984 to 2001, Mr. Cha had 17 years with various responsibilities within P&G, including the President of P&G Korea Professional Experience Chairman Cha – Top-notch Management with Global Vision and Track Record 9

Page 10

HYOUNG-JIN MOON Representative Executive Officer  REO, Hugel (‘23~current), with Hugel since 2021  Hospital Director, SH Plastic Surgery (‘20~’21)  Hospital director, Beup clinic (‘16~’20)  An internationally-renowned medical aesthetics expert previously serving the role of trainer for Allergen, Merz, Ipsen and Galderma  Yonsei University Medical School, Master of Science in Medicine EVA HUANG Chief Financial Officer  CFO, Hugel (’23~current)  Managing Director at CBC Group (’19~’23)  17+ years of Investment Banking and Private Equity and Corporate Finance  Harvard Business School, Executive Education  Peking University, Bachelor of Art (Financial Management) CHULMIN PARK Chief Human Resource Officer  CHO, Hugel (’18~current)  HR Lead, MUFG Seoul branch (’17~’18)  Head of HR, Bayer Material Science Korea Ltd. (‘14~’16)  Cornell University, MILR HYOJIN JEON Head of Strategy  Head of Strategy, Hugel (‘21~current)  Director, Samsung Card (’13~’21)  Project Leader, The Boston Consulting Group (’07~’13)  MIT Sloan School of Management, MBA SUK CHA, Executive Chairman  Executive Chairman, Hugel ('23~current)  Chairman, CEO, LG Household & Health Co., Ltd; Vice Chairman of LG Group Companies (‘05~’22)  President, CEO, Haitai Confectionary & Foods Co. Ltd (‘01~'04)  17+ years of various responsibilities within Procter & Gamble Korea, including the President, CEO(‘84~’01)  Cornell University MBA Experienced leaders within healthcare and medical aesthetic industry SANGBEOM LEE Chief Production Officer  CPO, Hugel (‘23~current)  39 years of production management at LG H&H, including 12 years as Chief Production Officer  Hongik University, Chemical Engineering Highly Experienced Management Team 10

Page 11

Total 25 new countries approvals obtained in the past two years (‘23~’24) China Europe The U.S. Apr ’19 Submitted toxin BLA (Letybo) Oct ’20 Obtained toxin approval (Letybo) Feb ’21 Toxin’s First product launch in China Jun ’20 Submitted toxin BLA (Letybo) Jan ’22 ~ ’24 YTD Obtained toxin approval in 38 European countries (Letybo) Mar ’22 Toxin’s First shipment to Europe Mar’ 21 Submitted 1st toxin BLA Apr ’22 Received NMPA approval for filler Q3 ’22 Filler product (Persnica) launched and shipped Oct ’18 Establishment of ‘Hugel America’ MENA LATAM ‘24‘23 Jan Jan Feb Jul ’23 Submitted 2nd toxin BLA Feb’24 Obtained FDA approval for Toxin (Letybo) Feb‘24 Obtained Filler approval on renewed syringes ‘12 Obtained filler approval Apr‘24 Filler’s First shipment after a syringe change Jan’24 Obtained approval for toxin in Kuwait Dec’23 Obtained approval for filler in Saudi Arabia Jul’24 Announced a Partnership Nov’23 Obtained approval for filler in Lebanon Mar’24 Obtained approval for toxin in Tunisia Apr’23 Obtained approval for filler In UAE Sep’21 Obtained approval for filler in Kuwait Q3 ’23 Change in toxin distribution method to nude vial Dec ’10 ~ ’’Jun 18 Obtained toxin approval in 10 LATAM countries and filler approval in 4 countries Jul’ 20 Obtained approval for filler in Ecuador Dec’ 20 Obtained approval for filler in Guatemala 2025 Expecting new Partnership in Brazil Q3 ‘24 First shipment to the U.S. T o x i n F i l l e r Apr Oct Nov Dec Jul Feb Jul Dec Sep Mar Oct Nov Key Markets Approval Timeline Key Markets Approval Highlight 11

Page 12

90,000 130,000 170,000 210,000 250,000 290,000 330,000 Share Price(KRW) 2022/03 M filed a complaint with the US ITC 2022/04 Aphrodite Consortium Acquired Hugel 2024/03 Received US FDA approval for toxin 2024/10: Final Determination ITC concluded "there is NO violation of Section 337" 2024/06: Initial Determination ITC ruled in favor of Hugel 2023/09 M withdrew trade secret claims regarding toxin strains 2024/01 M withdrew trade secret claims regarding manufacturing processes 2024/02 First trial of administrative lawsuit in Korea: Partial illegality of MFDS disposition due to abuse of discretion. Share Price Rallied Strongly with ITC Final Determination and US FDA Approval 12

Page 13

Delivered Solid Financials with Consistent Growth Net Sales EBITDA 281.7 319.7 363.8 FY2022 FY2023 3Q LTM 2024 116.0 131.6 172.6 FY2022 FY2023 3Q LTM 2024 YoY% 3Q LTM 2024 Financial Highlights Growth % +13.5% +13.8% YoY% Growth % +13.5% +31.1% (Unit: KRWbn) EBITDA margin, +6.3%pt improved from 2023 Gross Margin with further optimization space Total toxin vials sold in 2024 77% 47% 33% 77% of global total market supply16% 5 mn EBITDA margin, +6.3%pt improved from 2023 Net Income margin Cash Conversion rate Gross Margin with further optimization space Total toxin vials sold in 2024 of Global total market supply 13

Page 14

14 1 2 3 4 Table of Contents

Page 15

15Strictly Confidential Differentiated Price-to-Value Proposition with Long-standing Safety Track Record1 Committed to Medical Affairs with Strong Physician Engagement2 Proprietary Manufacturing Capabilities 3 Solid In-house R&D Capabilities and Pipeline4 Strong Financial with Steady Growth and Solid Margin Profile5 Hugel Highlights/ Advantages 15

Page 16

State-of-the-art Technology with safety track recordPrice-to-Value Proposition Affordable High-end Brands Precipitation Extraction Purification Lyophilization Cell culture & Fermentation Stringent Internal Regulations for Consistent & Stable Potency  Sophisticated testing method & process to stabilize potency  The highest purity level (99.5%) → Fast commercialization for various types of toxin  Optimal lyophilization (freeze-drying) → Comparable efficacy to the leading global brand Botulinum Toxin Hyaluronic Acid Filler STABILI- ZATION PURIFI- CATION BLENDING FILLING STERILI -ZATIONLINK Sterilization Cooling Method Other brands 110~120℃ Natural Cooling The Chaeum Ultra-high temperature Rapid Cooling Premium Brands Value Brands Affordable Brands Hugel  Quality products with reasonable price  Strong safety track record and engagement with physicians  White space with limited competition and approvals in most of the countries 1. Differentiated Price-to-Value Proposition with Long-standing Safety Track Record 16

Page 17

• Increase brand awareness by celebrity marketing across traditional and new channels B2C Customer and Global EngagementDifferentiated Training & Academic Support Conference & Symposium Brand Marketing Medical Aesthetics contents and workshops Bringing Innovative K-Aesthetics to Global KOLs • H.E.L.F | Hugel Expert Leader’s Forum since 2013 • H.O.P.E | Hugel Outstanding Professional Education • Provide seminars, workshops and cadaver sessions on the latest medical aesthetics trend  39 H.E.L.F. from 2013 to 2024  Total of 74 Medical Workshops conducts from 2021 to 2024 2. In-depth Expertise in Delivering Cutting-edge Aesthetic Contents 17

Page 18

5.7 5.0 Current 2025E~ Geodu A Sinbuk Geodu B x 2.3 (Unit: mn vials) 8.0 Botulinum Toxin Production Hyaluronic Acid Filler Production 4.0 4.0 4.0 Before 2021 2022~ x 2 3. Proprietary Manufacturing Capabilities (Unit: mn syringes) 18

Page 19

Hyaluronic Acid Filler Production and Utilization Rate 4. Solid In-house R&D Capabilities and Pipeline Glabellar lines Temporary improvement of facial wrinkles Penile enhancement Blepharospasm Glabellar lines Foot deformity in pediatric cerebral palsy Post-stoke upper limb spasticity Crow's feet Benign masseteric hypertrophy Cervical dystonia Overactive bladder Glabellar lines, Hyperhidrosis Submental fat reduction *Phase II clinical trial in progress in the U.S. Glabellar lines Revolax DEEP in Thailand Revolax FINE in Thailand Revolax DEEP in China Revolax SUB-Q in China BYRYZN in China 19

Page 20

68.1 78.1 95.6 113.8 133.3 166.2 33.3% 37.0% 41.2% 40.4% 41.7% 45.7% 2019 2020 2021 2022 2023 3Q LTM 2024 Gross Profit & Margin Operating Profit* & Margin EBITDA* & Margin Net Income* & Margin [Unit: KRWbn] 143.9 148.8 177.1 218.9 246.2 278.5 70.4% 70.5% 76.4% 77.7% 77.0% 76.5% 2019 2020 2021 2022 2023 3Q LTM 2024 50.3 66.8 60.4 73.1 113.2 129.1 24.6% 31.6% 26.0% 26.0% 35.4% 35.5% 2019 2020 2021 2022 2023 3Q LTM 2024 77.5 88.8 111.4 128.4 147.1 182.3 37.9% 42.1% 48.0% 45.6% 46.0% 50.1% 2019 2020 2021 2022 2023 3Q LTM 2024 * For 2022~23 OP, EBITDA and net income, the data included normalized number, excluding one-time service fees, such as ITC expense 5. Strong Financial Profile with Steady Growth and Solid Margin 20

Page 21

1 2 3 4 Table of Contents 21

Page 22

Strategy for Future Growth Upside Business Opportunities New Product/ Indication Initiatives  Continued business expansion in the Cosmeceuticals segment in key international markets  Differentiate toxin and filler with new indications and formulations  Proactive business development of new product category M&A Pipeline  Stay focused on the core category of injectable segment providing a clear synergy with existing platform  Prioritize targets with high entry barrier, propitiatory ingredient or production knowhow Organic Business Strategy Maintain Market Leadership in Korea  Solidify market leadership in Korea for both toxin and filler with differentiated product strategy  Further penetration among existing customers  Continue to lead the physician training and education programs, medical aesthetic conferences Deliver International Growth  Build market leadership in key international markets  Further penetration in emerging markets such as South East Asia, MENA and LATAM Further Margin Enhancement  More revenue stream from higher ASP markets  New toxin manufacturing facility becoming operational within 1H 2025, further improving efficiency and achieving further optimized COGS  Tightened SG&A control for calculated expansion 22

Page 23

Industry-leading Margins and Growth Surpassing PeersDomestic Market Achievement #1 Filler Market Share Market Share (2023) Hugel Other Peers 39% 21% 15% 12% 6% 1% 6% #1 Toxin Market Share 1,795 3,296 2023-12-28 2025-01-152023-12-28 Hugel’s Market Cap 2025-01-15 (Unit: KRWbn) EBITDA Margin (3Q LTM 2024) 16.2% 6.9% 5.3% 8.7% 3.8% 7.5% Avg. ’21~3QLTM 2024 Revenue Growth CAGR Hugel M D H I 47.4% 22.9% 13.0% 33.1% 35.5% Hugel M D H I 30.7% Avg. ’3Q LTM 2024 EBITDA Margin Revenue Growth (2021-3Q LTM 2024 CAGR) 1. Continue to Maintain Leadership Positioning in Korea 18% 16% 11% 10% 10% 6% 10% 10% 9% 23

Page 24

2. Well Poised to Capture Key International Expansion Opportunities U.S. 2022 Toxin Entry Year 2012 Filler Entry Year LATAM AP(ex-CH) EU USD0.6bn USD1.1bn China Toxin market size Filler market size Filler market size USD0.8bn USD1.5bn Toxin market size 2020 Toxin Entry Year 2022 Filler Entry Year USD2.5bn USD1.5bnFiller market size Toxin market size USD0.5bn USD0.5bnFiller market size Toxin market size USD0.4bn USD0.6bnFiller market size Toxin market size T oxin Filler 67 80 52 70 2024 Toxin Entry Year • Korea • Thailand • Philippines • India • Mongolia • Taiwan • China • Malaysia • Indonesia • Australia • Japan • Georgia • Russia • France • Austria • Netherlands • Romania • U.K. • Ireland • Portugal • Italy • Germany • Poland • Armenia • Belarus • Kazakhstan • Azerbaijan • Spain • Malta • Hungary • Belgium • Denmark • Cyprus • Sweden • Finland • Luxembourg • Czech Republic • Greece • Norway • Slovakia • Switzerland • Latvia • Croatia • Liechtenstein • Iceland • Bulgaria • Lithuania • Estonia • Slovakia • Moldova • Turkiye • Kuwait • UAE • Saudi Arabia • Lebanon • Tunisia • Bosnia Herzegovina • U.S.A • Canada • Honduras • El Salvador • Costa Rica • Guatemala • Dominican Republic • Panama • Peru • Uruguay • Paraguay • Bolivia • Chile • Ecuador • Colombia • Brazil Countries to be presented until 2028 • Serbia • Slovenia 24

Page 25

2. Besides Long-tail ROW markets 4,000 2,324 403 312 289 235 222 205 173 188 138 159 189 141 122 114 94 90 88 74 60 58 59 48 52 47 46 41 45 36 29 In US$mn Hugel’s current capabilities enable it to compete in a large global addressable market, with detailed strategies to establish itself as a global, widely -recognized brand even in RoW markets The Top 15 RoW toxin and filler markets account for around USD3bn in market size, representing a larger market than the entire Europe Key RoW markets Hugel’s key markets Other RoW markets Toxin and Filler Market Size in 2024 of Hugel’s Key Markets Continuous growth in key countries, as well as, RoW markets representing attractive opportunity for Hugel to expand internationally 25

Page 26

2. Prioritized International Markets Overview Market Size(2024) Aesthetic only Approval Timeline Strategy China  Toxin: USD800~900mn  Filler: USD1.5bn  Toxin: Approved in October 2020  Filler: Approved in April 2022  Partnered with Sihuan  Achieved 10% toxin M/S within 1 year of launch and Target 20-25% M/S by 2027 EU  Toxin: USD600mn  Filler: USD1.1bn  Toxin: Approved in February 2022  Filler: Obtained CE in 2012  Toxin Partnered with Croma Pharma  Target 20~25% toxin M/S by 2027 US  Toxin: USD2~2.5bn  Filler: USD1.5bn  Toxin approval obtained in February 2024  Target 10% toxin M/S within 3 years of launch  Partner’s solid sales network and Hugel's accumulated expertise in academic marketing MENA  Toxin: USD140mn  Filler: USD280mn  Toxin: Approval in Kuwait in 2024/ Approval expected in UAE and Saudi Arabia inQ1 2025  Filler: Approved in UAE, Saudi Arabia, Kuwait, Lebanon, and Tunisia  Partnered with Medica Group  Target 30% toxin M/S within 3 years of launch LATAM  Toxin: USD400mn  Filler: USD600mn  Toxin: Approved in Brazil, Chile, Colombia, Peru, etc. /Mexico expected in 1H 2026  Filler: Approved in 5 countries/ Brazil and Mexico’s approval under review  Top 3 player in local markets 26

Page 27

28% 9% 2. Key International Market Strategy 1) China Only Korean Toxin Brand leveraging K-beauty influence in China  Leveraging on its differentiated positioning to gain market share China Aesthetic Botulinum Toxin Market Size Hugel’s Differentiation Points Continue to strengthen No.1 market share in 50IU leveraging China government’s campaign, ‘1 patient 1 vial’ 1 Tailored KOL engagement and partnership with the large chain institutions by active medial affairs and educational programs 2 Further penetration opportunities to lower tier cities3 Differentiated Product Positioning Key StrategiesMedical Aesthetics Penetration of Accessible Population  Current low penetration in China implies tremendous future market opportunities 2024 2030 0.8 3.5 17050301016030 Accessible Population (in mn) 27

Page 28

2. Key International Market Strategy 2) Europe Key Achievements Market Characteristics Toxin  Germany: Top 2 market share in 2023  Poland: Top 3 market share in 2023 Future Growth Strategy Strengthen Position in U.K., France, Italy Become a well-known, affordable brand. More potential to expand market share other Europe markets as UK, France, Italy and SpainStronger physician training and engagement 21.7 31.5 36.5 7.8 8.6 2021 2022 2023 Toxin Filler (Unit: KRWbn) Toxin & Filler Sales Trend (‘21~’23) Filler  Top 5 in major EU markets, UK, France, Germany, Italy, Spain, Poland with the high awareness of Hugel’s filler Oligopoly market led by the three leading global companies Limited entry of new players due to sale support requirements (i.e. relationship building with clinics and physicians) Incumbents focuses on different target sales channel (i.e. hospitals in major cities, local hospitals, urban and rural clinics) 28

Page 29

2. Key International Market Strategy 3) The U.S. Unique price-to-value proposition 3 Providing value-added Services to physicians 2 Targeted distribution channels1 Future Growth Strategy Clear Positioning of Market Entry Capture the Incremental Market Growth and achieve 10% M/S within 3 years of the launchTargeted & Focused Channel Strategy Comprehensive Physician engagement 4.9 2.5 2024 2030 The U.S. Aesthetic Botulinum Toxin Market Size The U.S. Market Opportunity Hugel’s Differentiation Points 29

Page 30

2. Key International Market Strategy 4) LATAM Sales Trend in LATAM (2020~23)Market Characteristics Key Achievements 2020 2021 2022 2023 Rest of LATAM Brazil (Unit: KRWbn) 4.8 20.8 11.0 22.5 2 Growing Demand for minimally invasive procedures, particularly botulinum toxin 1 LATAM Aesthetics Toxin market estimated to be USD 480-500mn in 2024, growing at high-single digits per annum 4 Changing lifestyles: The changing lifestyles of a high middle-income patient pool is driving growth 3 Increasing Consumer Base: Diverse demographics by societal acceptance, improved accessibility and shifting perceptions about beauty and self-care  Increased market engagement and marketing collaboration with distributor  Establish a comparable premium position through value-add services such as regular hands-on training programs, Korea visits(GLAM) for clinic tour  Brazil: ~20% toxin market share in 2023. Optimize sales with new distributor expected in 2025 *Source: https://www.arizton.com/market-reports/brazil-medical-aesthetics-market 30

Page 31

2. Key International Market Strategy 5) MENA Market Characteristics* Strengthened partnership with Medica Group  The increasing number of aesthetic procedures  Advanced healthcare infrastructure  The growing number of medical tourism  The diverse and affluent population Becoming a regional healthcare innovation hub and a medical tourism destination UAE  Rapidly increasing aging population  Increasing obese population  Increasing awareness regarding aesthetic procedures  Rising adoption of minimally invasive device  More influence of social media Experiencing growth driven by the increasing demand for non-surgical and minimally invasive aesthetic procedures - shorter recovery times and reduced risks Saudi Arabia *Source: https://www.mordorintelligence.com/industry-reports/uae-aesthetic-devices-market https://www.mordorintelligence.com/industry-reports/saudi-arabia-aesthetic-devices-market Medica Group - headquartered in Dubai, is a leading aesthetic and medical distribution partner with a 20+ year history Robust Distribution Networks Solid Know-how and strong execution capabilities At least achieve 30% of the market share within 3 years of the launchCollaboration w/ Partner 31

Page 32

3. Continuous Margin Improvement from Higher ASP Markets Korea China Europe GCC The U.S. Sales growth opportunities from higher ASP markets internationally Comparative Price Comparison between Korea and Key International Markets (Indicative Only) 32

Page 33

1 2 3 4 Table of Contents 33

Page 34

Capital Allocation Plan 34

Page 35

Recap: Strategy for Future Growth Upside Business Opportunities New Product/ Indication Initiatives  Continued business expansion in the Cosmeceuticals segment in key international markets  Differentiate toxin and filler with new indications and formulations  Proactive business development of new product category M&A Pipeline  Stay focused on the core category of injectable segment providing a clear synergy with existing platform  Prioritize targets with high entry barrier, propitiatory ingredient or production knowhow Organic Business Strategy Maintain Market Leadership in Korea  Solidify market leadership in Korea for both toxin and filler with differentiated product strategy  Further penetration among existing customers  Continue to lead the physician training and education programs, medical aesthetic conferences Deliver International Growth  Build market leadership in key international markets  Further penetration in emerging markets such as South East Asia, MENA and LATAM Further Margin Enhancement  More revenue stream from higher ASP markets  New toxin manufacturing facility becoming operational within 1H 2025, further improving efficiency and achieving further optimized COGS  Tightened SG&A control for calculated expansion 35

Page 36

Page 37

Thank you 37

Slides